Skip to content

Volume 3D_US Kidney

Measurement of Kidney Volume and Renal Tumor Volume Using 3D-Ultrasound Imaging

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03841149
Acronym
VolUS3D
Enrollment
53
Registered
2019-02-15
Start date
2020-06-29
Completion date
2023-09-11
Last updated
2026-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Diseases, Renal Tumor

Keywords

3D Ultrasound volume measurements, Renal volume, Tumour Volume

Brief summary

The purpose of this study is to measure the volume of the kidney and tumors using 3D-US acquisition and to correlate these measurements to contrast-enhanced CT or MRI.

Detailed description

Additional objectives are comparison between true volume measurements and volume estimation using measurements of the three perpendicular diameters, comparison of inter and intra variability of 3D US measurements with inter and intra variability of 3D CT or MRI measurements, calculation of 3D and 2D volume measurements during contrast-enhanced US examination when the injection is performed for clinical routine purposes such as vascular and extension staging, during interventional procedures such as US guided biopsy targeting the non-necrotic tumour parenchyma. Concordance between 2D and 3D US acquisitions will be compared to CT and MRI measurements. Comparison of volume measurements between non-contrast and contrast-enhanced methods (US, CT and MRI) will be performed. The results will be compared to renal function before and after tumour treatment.

Interventions

OTHERUltrasound Imaging

3D volume calculation using on-line and off-line softwares

Sponsors

Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER
URC-CIC Paris Descartes Necker Cochin
CollaboratorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult patient (age 18) * Absence of participant's opposition * No contra-indication to contrast-enhanced CT AND MRI (a single contrast-enhanced imaging modality is sufficient) * Affiliated to Social Security

Exclusion criteria

\- Contra-indication to both contrast-enhanced CT AND MRI

Design outcomes

Primary

MeasureTime frameDescription
3D-US volume measurements1 monthKidney and renal tumor

Secondary

MeasureTime frameDescription
2D-US volume measurements1 monthKidney and renal tumor
Inter and intra variability measurements1 monthKidney and renal tumor
2D and 3D US volume measurements during Contrast-enhanced US (if performed for patient management)1 monthKidney and renal tumor

Countries

France

Contacts

PRINCIPAL_INVESTIGATORJean-Michel Correas, PU-PH

Assistance Publique - Hôpitaux de Paris

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 4, 2026